Endothelial cells internalize and degrade RGD-modified proteins developed for tumor vasculature targeting
Authors:
- Robbert J KokRKRobbert J Kok
- Agnes D BerendsenABAgnes D Berendsen
- Henk E MoorlagHMHenk E Moorlag
- Erwin J BosEBErwin J Bos
- Dirk K.F MeijerDMDirk K.F Meijer
- Lou F.M.H de LeijLLLou F.M.H de Leij
- Grietje MolemaGMGrietje Molema
- 1 October 2002
- journal article
- Published by Elsevier in Journal of Controlled Release
- Vol. 83 (2) , 241-251
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- The role of αv integrins during angiogenesis: insights into potential mechanisms of action and clinical developmentJournal of Clinical Investigation, 1999
- Decreased angiogenesis and arthritic disease in rabbits treated with an αvβ3 antagonistJournal of Clinical Investigation, 1999
- Tumor Infarction in Mice by Antibody-Directed Targeting of Tissue Factor to Tumor VasculatureScience, 1997
- Ligation of Integrin α5β1 Is Required for Internalization of Vitronectin by Integrin αvβ3Journal of Biological Chemistry, 1997
- Phage Libraries Displaying Cyclic Peptides with Different Ring Sizes: Ligand Specificities of the RGD-Directed IntegrinsNature Biotechnology, 1995
- Integrin transmembrane signaling and cytoskeletal controlCurrent Opinion in Cell Biology, 1995
- Integrin αvβ3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vesselsCell, 1994
- Requirement of Vascular Integrin α v β 3 for AngiogenesisScience, 1994
- Vitronectin receptor-mediated phagocytosis of cells undergoing apoptosisNature, 1990
- Preparation of Iodine-131 Labelled Human Growth Hormone of High Specific ActivityNature, 1962